1.	An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MM-016, FHCRC-2068.00, CELGENE-CC-5013-MM-016, NCT00179647
2.	Lenalidomide and Dexamethasone With/Without Transplant in Patients With Multiple Myeloma Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCI 07-134, NCT00777881
3.	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LENA-LMA-5, NCT01198054
4.	Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AAAJ2355, NCT01731886
5.	Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02057, E3A06, ECOG-E3A06, CDR0000682012, U10CA021115, NCT01169337
6.	Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Phase: Phase III Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00522, E1A06, CDR0000583984, ECOG-E1A06, U10CA021115, NCT00602641
7.	Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00798, S0777, U10CA032102, CDR0000590321, SWOG-S0777, NCT00644228
8.	A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-CLL-002, NCT00774345
9.	Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: LenaMain-Trial, NCT00891384
10.	A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q Phase: Phase III Type: Health services research, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-5013-MDS-005, NCT01029262
11.	The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 60 to 75 Sponsor: Other Protocol IDs: DSMM XIII, NCT01090089
12.	Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: RV-MM-EMN-441, NCT01091831
13.	Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Phase: Phase III Type: Treatment Status: Active Age: 70 and under Sponsor: NCI, NHLBI Protocol IDs: 690, NCT01109004
14.	Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP Phase: Phase III Type: Treatment Status: Active Age: 60 to 80 Sponsor: Other Protocol IDs: REMARC, NCT01122472
15.	Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 10-106, NCT01208662
16.	Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: HOVON 95 MM, 2009-017903-28, EMN02, NCT01208766
17.	Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SINTRA-REV, 2009-013619-36, NCT01243476
18.	Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA204-006, 2010-022445-20, NCT01335399
19.	Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RV-FOL-GELARC-0683C, 2011-002792-42, NCT01476787
20.	Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 2081-113, NCT01530594
21.	Use of Thalidomide, Lenalidomide, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: EudraCT number: 2009-010956-93, NCT01554852
22.	A Phase 3 Study of the Efficacy and Safety of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CLLM1 Protocol of the GCLLSG, 2011-004698-98, RV-CLL-GCLLSG-0725, NCT01556776
23.	A Phase 3 Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C16010, 2011-005496-17, NCT01564537
24.	Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UARK 2009-09, NCT01621672
25.	A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: RV-FOL-GELARC-0683, 2011-002792-42, NCT01650701